In wake of Bio­gen's skir­mish with the SEC, phar­ma gi­ants are chang­ing the way they do quar­ter­ly re­ports

Af­ter re­ceiv­ing com­plaints from the SEC last spring, Bio­gen changed the way it re­ports up­front pay­ments to col­lab­o­ra­tors in its quar­ter­ly up­dates. But it ap­pears Bio­gen wasn’t the on­ly one who got the mes­sage.

Sev­er­al phar­ma gi­ants — in­clud­ing Eli Lil­ly, Mer­ck, Bris­tol My­ers Squibb, Ab­b­Vie and Pfiz­er — are mak­ing sim­i­lar changes in this year’s Q1 re­sults, ac­cord­ing to Mar­ket Watch, which first re­port­ed the news. The changes re­volve around cer­tain fig­ures that don’t com­ply with Gen­er­al­ly Ac­cept­ed Ac­count­ing Prin­ci­ples, al­so known as non-GAAP mea­sures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.